SAWAI GROUP HOLDINGS Co., Ltd. Logo

SAWAI GROUP HOLDINGS Co., Ltd.

4887 | T

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
Japan
Address:
大阪市淀川区宮原5丁目2−30
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

SAWAI GROUP HOLDINGS Co., Ltd. is a Japanese company dedicated to promoting healthy living. With a focus on enhancing the well-being of communities, the group engages in various health-centered initiatives, including partnerships aimed at improving health among the elderly. The company operates through subsidiaries like FrontAct, which offers innovative health monitoring solutions. Committed to sustainability and corporate governance, SAWAI GROUP HOLDINGS prioritizes environmental and social responsibilities as part of its long-term vision. Through strategic investments and a commitment to quality, the company strives to be a leader in the healthcare sector, ensuring a healthier future for all.

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for SAWAI GROUP HOLDINGS Co., Ltd.. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-06-27 02:47
Regulatory News Service
訂正発行登録書
Japanese 10.0 KB
2025-06-26 07:49
Regulatory News Service
臨時報告書
Japanese 31.2 KB
2025-06-24 08:06
Regulatory News Service
内部統制報告書-第4期(2024/04/01-2025/03/31)
Japanese 24.3 KB
2025-06-24 08:06
Regulatory News Service
確認書
Japanese 9.0 KB
2025-06-24 08:05
Annual Report
有価証券報告書-第4期(2024/04/01-2025/03/31)
Japanese 2.0 MB
2025-05-27 05:40
Regulatory News Service
訂正発行登録書
Japanese 9.6 KB
2025-05-27 02:50
Regulatory News Service
臨時報告書
Japanese 20.1 KB
2025-04-03 06:28
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 23.4 KB
2025-03-05 07:02
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 27.8 KB
2025-02-05 07:08
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 28.2 KB
2025-01-08 07:53
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 27.7 KB
2024-12-04 07:05
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 28.5 KB
2024-11-11 07:47
Regulatory News Service
確認書
Japanese 9.1 KB
2024-11-11 07:46
Interim Report
半期報告書-第4期(2024/04/01-2025/03/31)
Japanese 350.6 KB
2024-11-06 07:08
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 28.7 KB

Automate Your Workflow. Get a real-time feed of all SAWAI GROUP HOLDINGS Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for SAWAI GROUP HOLDINGS Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Swedish Orphan Biovitrum Logo
Develops innovative therapies for rare diseases in haematology, immunology, and specialty care.
Sweden SOBI
SymBio Pharmaceuticals Limited Logo Japan 4582
Synbiotic SE Logo
A vertically integrated European group for the entire hemp and cannabis value chain.
Germany SBX
Synektik S.A. Logo
Radiopharmaceuticals, medical devices & IT solutions for oncology, cardiology, and neurology.
Poland SNT
Synthaverse S.A. Logo
Develops and sells oncology, hematology, and immunology drugs and vaccines globally.
Poland BML
TAIKO PHARMACEUTICAL CO., LTD. Logo Japan 4574
Takeda Pharmaceutical Company Limited Logo Japan 4502
TAUNS Laboratories, Inc. Logo Japan 197A
Tchaikapharma High Quality Medicines AD Logo
Manufactures affordable generic & complex polypill medicines for socially significant diseases.
Bulgaria THQM
Teva Pharmaceutical Industries Ltd. Logo
A global leader in generic drugs and innovative medicines for CNS and immuno-oncology.
Israel TEVA